Theramex Negotiates FDA Import Permit for Estrogen Patches
Theramex is negotiating with the FDA to import Evorel estrogen patches into the U.S. to address rising demand and reported medication shortages.
Theramex, a London-based pharmaceutical company, is negotiating with the U.S. Food and Drug Administration to supply its Evorel estrogen patches to the United States. The company has scaled up production to respond immediately if the FDA issues a special import permit, as Theramex currently has no approved products in the U.S. market.
The move follows a surge in demand for estradiol prescriptions, which have doubled to 4 million monthly over the last two years. While the American Society of Health-System Pharmacists has listed the patches as being in shortage since January, the FDA does not officially classify them as being in nationwide short supply.
Theramex plans to formally seek FDA approval for the patches in the first half of 2027 and is currently discussing U.S. distribution with an unnamed business partner. Sarah Ibrahim, the FDA's deputy director for regulatory programs, acknowledged that some patients have faced frustration regarding medication access over the past few months.